title: Angiotensin-converting enzyme gene I/D polymorphism in malignant hypertension.
abstract: BACKGROUND
  The mechanism of the rapid transition of a stable benign hypertensive disease to a severe and devastating malignant hypertension is not fully understood. However, the renin angiotensin system, which is highly activated in malignant hypertension, is established as an important pathogenetic factor in different cardiovascular and renal diseases. Over the last decade, a polymorphism in genes regulating this system has been found. This includes the 287 bp sequence deletion (D)/insertion (I) polymorphism in the angiotensin-converting enzyme (ACE) gene and the methionine (M) to threonine (T) point mutation polymorphism in the angiotensinogen (AGT) gene. These gene polymorphisms have been associated with various cardiovascular and renal diseases and the aim of this study was to investigate whether they were linked to malignant hypertension.
  
  
  METHODS
  Forty-two patients with malignant hypertension (mean age 55 years), 42 patients with non-malignant hypertension (mean age 57 years) and 85 normotensive control subjects (mean age 42 years) were investigated with respect to ACE I/D and AGT M/T genotypes. DNA was prepared by standard methods from isolated white blood cells and analysed by the PCR technique. The PCR reaction used in the detection of the ACE I/D polymorphism was optimized for an equal amplification of the I and D alleles.
  
  
  RESULTS
  The frequency of the DD genotype was significantly increased in patients with malignant hypertension (43%) compared with patients with non-malignant hypertension (14%) and normotensive control subjects (18%) (p <0.01) for both. The frequency distribution of AGT M/T genotype did not differ between patients with malignant and non-malignant hypertension.
  
  
  CONCLUSIONS
  The DD genotype of the ACE gene occurred more than twice as often in malignant hypertension than in non-malignant hypertension and indicates that ACE gene polymorphism is a significant risk factor for initiation of malignant hypertension.
authors.affiliation: Department of Nephrology, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Stefansson
authors.forename: A
authors.initials: A
authors.lastname: Ricksten
authors.forename: L
authors.initials: L
authors.lastname: Rymo
authors.forename: M
authors.initials: M
authors.lastname: Aurell
authors.forename: H
authors.initials: H
authors.lastname: Herlitz
mesh_terms: D000328:Adult; D004251:DNA Transposable Elements; D005260:Female; D017353:Gene Deletion; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000235:genetics; D006974:Hypertension, Malignant / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D012016:Reference Values
chemical_list: D004251:DNA Transposable Elements; D007703:Peptidyl-Dipeptidase A